Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

DOI: 10.1634/theoncologist.2016-0148

Keywords: KRAS, Colon cancer, Biomarker, Genomic profiling, Epidermal growth factor receptor, Cetuximab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text